

Disclaimer :

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudices the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

M. 8192 – ADVENT INTERNATIONAL / THL / INVENTIV

SECTION 1.2

Description of the concentration

1. The notified concentration involves the proposed acquisition by funds managed by Advent International Corporation (“**Advent International**”) and funds affiliated with Thomas H. Lee Partners, L.P. (“**THL**”) (together, the “**Notifying Parties**”) of joint control of inVentiv Health, Inc. (“**inVentiv**” or “**Target**”) (together with Advent International and THL, the “**Parties**”) (the “**Proposed Transaction**”) within the meaning of Article 3(1)(b) of the EU Merger Regulation.
2. inVentiv is currently solely controlled by funds affiliated with THL.
3. Advent International is a private equity investor based in Boston. Advent International focuses on (i) the acquisition of equity stakes (both controlling and non-controlling) in companies where it believes that an injection of capital would improve the company’s future prospects for growth, and (ii) the management of investment funds. As a private equity investor, Advent International has holdings in various sectors, including industrial, retail, media, communications, information technology, internet, healthcare and pharmaceuticals.
4. THL is a private equity firm investing in growth-oriented global businesses, headquartered principally in North America, across three broad sectors: (i) Consumer & Healthcare, (ii) Media & Information Services and (iii) Business & Financial Services. THL’s team of investment and operating professionals partner with portfolio company management teams to identify and implement business process improvements that accelerate sustainable revenue and profit growth.
5. inVentiv is a global provider of outsourced clinical development and commercialisation services predominantly to biopharmaceutical companies.